Immunotherapy of Gastrointestinal Stromal Tumors.
10.3881/j.issn.1000-503X.11097
- Author:
Chang Zhen ZHU
1
;
Dong LIU
1
;
Wei Ming KANG
1
Author Information
1. Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor T-cell immunotherapy;
gastrointestinal stromal tumors;
immune checkpoint suppression;
immunotherapy
- MeSH:
Gastrointestinal Stromal Tumors;
immunology;
therapy;
Humans;
Immunotherapy;
Mutation;
Proto-Oncogene Proteins c-kit;
genetics;
Receptor, Platelet-Derived Growth Factor alpha;
genetics;
Tumor Microenvironment
- From:
Acta Academiae Medicinae Sinicae
2019;41(5):696-701
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumors(GISTs)are the most common mesenchymal tumors of the gastrointestinal tract and respond poorly to conventional radiochemotherapy.Complete excision is the only possible way to cure GISTs.Although targeted therapy is effective for GISTs,multiple and/or secondary mutations of KIT or PDGFRA gene have lead to increased drug resistance and disease relapse.A variety of tumor infiltrating immune cells and complex immune microenvironments have been found in GISTs.Many immune cells participate in the occurrence and development of GISTs and play key roles in targeted therapy.The feasibility and effectiveness of immunotherapy for GISTs have been well demonstrated in preclinical and clinical studies.
